PCOS Is Now PMOS — What the Name Change Means for Your Health in Midlife
On May 12, 2026, a landmark paper published in The Lancet announced that polycystic ovary syndrome — PCOS — will be officially renamed polyendocrine metabolic ovarian syndrome, or PMOS. This was not a cosmetic adjustment. It was the culmination of a 14-year global consensus process involving 56 leading academic, clinical, and patient organizations, and informed by surveys gathering input from more than 14,300 people living with the condition and health professionals from every region of the world.
The driving logic behind the change is straightforward and long overdue: the old name was inaccurate. It emphasized ovarian cysts — which are not consistently present, are not a diagnostic criterion in all frameworks, and are not the defining feature of the condition. It obscured the endocrine and metabolic dimensions that are often more clinically significant than the reproductive symptoms. And it contributed to delayed diagnosis, fragmented care, and a narrowly reproductive framing of a condition that affects women's health across their entire lifespan.
The new name — polyendocrine metabolic ovarian syndrome — reflects what the condition actually is: a complex hormonal disorder involving androgen excess, disrupted ovulation, and a cluster of metabolic and endocrine features that have real implications for cardiovascular health, insulin regulation, and long-term wellbeing.
The new name — polyendocrine metabolic ovarian syndrome — reflects what the condition actually is.
What PMOS Actually Is
PMOS affects more than one in eight women worldwide, making it one of the most prevalent hormonal conditions in women's health — and one of the most commonly misunderstood.
At its core, PMOS is characterized by hormonal dysregulation. This typically involves androgen excess — elevated levels of hormones like testosterone — along with disrupted ovulation, and often the presence of multiple small follicles on the ovaries visible on ultrasound. Because ovulation is disrupted, the progesterone that is normally produced following ovulation may be inconsistently or insufficiently produced. Over time, this creates a hormonal environment with implications far beyond menstrual irregularity.
The condition presents differently at different life stages. In younger women, the picture often looks primarily reproductive: irregular periods, challenges with conception, acne, excess facial or body hair, and pregnancy complications. As women move into their thirties, forties, and beyond, the metabolic dimensions often become more prominent: insulin resistance, difficulty maintaining a healthy weight, abnormal lipid levels, elevated cardiovascular risk, and sleep apnea. The condition does not resolve at menopause — it simply changes shape.
Why the Name Change Matters for Women in Midlife
The reframing from PCOS to PMOS is especially significant for women navigating perimenopause and menopause. For many years, the prevailing clinical assumption was that PCOS was primarily a concern during the reproductive years — something to manage for fertility purposes, and less relevant once menstrual cycles became irregular and fertility concerns receded.
The research does not support that assumption. Women with PMOS carry elevated cardiovascular risk, insulin resistance, and metabolic vulnerability that continue — and in some cases intensify — through the menopause transition. Changes in estrogen levels, shifts in body composition, and the natural reduction in muscle mass and increase in visceral fat that accompany menopause can make previously manageable PMOS features suddenly more pronounced. Women who were metabolically compensated before the transition may find that perimenopause tips that balance in a way that demands more active clinical attention.
The new name creates both the language and the expectation for this kind of longitudinal, metabolic framing. A diagnosis of PMOS should now prompt ongoing clinical conversation about metabolic health — blood sugar, cholesterol, blood pressure, liver health, sleep apnea, and cardiovascular risk — throughout midlife, not only during the years when reproductive concerns are central.
The Overlap With Perimenopause — and Why It Creates Diagnostic Complexity
One of the most practically challenging aspects of PMOS in midlife is how significantly its symptoms overlap with perimenopausal symptoms, making it difficult to determine what is driving what.
Both conditions involve substantial hormonal fluctuation. Both can produce irregular menstrual cycles, sleep disruption, mood changes, shifts in body composition, brain fog, and worsening insulin resistance. Low progesterone — a feature of both PMOS-related anovulation and the perimenopausal decline in ovarian function — is implicated in many of these shared symptoms.
Interestingly, research suggests that women with PMOS tend to reach menopause somewhat later than women without the condition, which can mean a longer perimenopausal window with greater hormonal variability. This extended exposure to fluctuating hormones has its own implications for symptom severity and metabolic risk.
Because no single test confirms perimenopause, and because PMOS can persist through and beyond it, identifying what is driving symptoms in midlife women with PMOS often requires looking at the full clinical picture rather than searching for one explanation. A provider who understands both conditions, and who approaches them through an integrated metabolic and endocrine lens, is essential for navigating this overlap effectively.
How to Manage PMOS Through the Menopause Transition
The lifestyle foundations that support PMOS management are largely the same ones that support a healthy menopause transition — which means that addressing both conditions simultaneously is genuinely possible through a coherent strategy.
Maintaining a healthy body composition. The relationship between weight and PMOS features is well documented. Even modest weight reduction in women with PMOS — in the range of 5 to 10 percent of body weight — has been shown to improve hormonal parameters, insulin sensitivity, and cycle regularity. During perimenopause, when weight redistribution toward the abdomen naturally increases, prioritizing resistance training and adequate protein intake supports both goals simultaneously.
Nutritional strategies that support insulin sensitivity. A diet centered on whole foods, adequate protein, fiber-rich vegetables and legumes, and limited refined carbohydrates and processed foods directly addresses the insulin resistance that is a core feature of PMOS and that worsens during the metabolic changes of menopause. This is not a restrictive approach — it is a supportive one.
Sleep quality. PMOS is associated with elevated risk of obstructive sleep apnea — a connection that is frequently under-recognized and under-screened. If you experience symptoms such as daytime fatigue, frequent waking, loud snoring, or morning headaches, this is worth raising explicitly with your provider. Sleep apnea compounds both metabolic and cardiovascular risk, and treating it produces measurable improvements in metabolic markers.
Ongoing cardiovascular and metabolic screening. Women with PMOS should have regular monitoring of blood pressure, fasting glucose or hemoglobin A1c, lipid panel, and liver function — particularly as they move through perimenopause and into postmenopause, when background cardiometabolic risk is rising. This screening should be proactive, not reactive.
Finding a provider who understands the full picture. The reframing from PCOS to PMOS is the beginning of a shift in clinical practice that will take years to fully propagate. In the interim, you may need to advocate explicitly for a metabolic and endocrine framing of your care, rather than accepting a purely reproductive one. If your current provider continues to treat PMOS only through the lens of menstrual regulation or fertility, it may be worth seeking consultation with an endocrinologist or a menopause specialist with metabolic expertise.
Defy Menopause - Own the Change
Many women tell me: "One day I feel amazing. The next, I can barely get out of bed. Is this normal?"
Yes, it is. And no, you don’t have to suffer through it alone.
Hormonal fluctuations during perimenopause can make you feel like you’ve lost control of your body. But knowledge is powerful. And there are clear, science-backed ways to support your hormones, ease symptoms, and reclaim your energy.
That’s exactly why I created Defy Menopause: Own the Change — a 30-day program designed to give you the tools, knowledge, and support you need to move through these changes with clarity and confidence.
Inside, you’ll find:
Access to Dr. Tracy Verrico at one (1) live, group session
Clear action steps for managing symptoms naturally
Because you deserve more than just "putting up with it."
You deserve to thrive.
Let’s Connect
Schedule an Appointment | LinkedIn | YouTube | Instagram | Bona Dea Gynecology
Medical Disclaimer: The information provided in this blog is for general educational and informational purposes only and is not intended as, nor should it be considered, medical advice. This content does not establish a physician-patient relationship and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read in this newsletter. If you think you may have a medical emergency, call your doctor or emergency services immediately.
References
Teede HJ, Tay CT, Laven J, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-2469.
Azziz R, et al. Proposed renaming of polycystic ovary syndrome: polyendocrine metabolic ovarian syndrome (PMOS). The Lancet. 2026.
World Health Organization. Polycystic Ovary Syndrome Fact Sheet. who.int. Updated 2023.
Joham AE, Norman RJ, Stener-Victorin E, et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol. 2022;10(9):668-680.
Kahal H, Kyrou I, Uthman OA, et al. The prevalence of obstructive sleep apnoea in women with polycystic ovary syndrome. Sleep Med Rev. 2020;51:101275.
Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2011.
Daan NM, Louwers YV, Koster MP, et al. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk? Fertil Steril. 2014;102(5):1444-1451.
